Copyright
©The Author(s) 2022.
World J Clin Oncol. May 24, 2022; 13(5): 314-322
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.314
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.314
Study | Phase | Stages | Treatment | Cycles | Patients included | Main endpoint | ORR | MPR | pCR |
Forde et al[8] | I | I-IIIA | Nivolumab | 2 | 21 | Safety and feasibility | 10% | 45% | 10% |
LCMC3[14] | II | IB-IIIB | Atezolizumab | 2 | 181 | MPR | 7% | 20% | 7% |
NEOSTAR[18] | II | I-IIIA | Nivolumab vs nivolumab + ipilimumab1 | 3 | 44 | MPR | 22% vs 19% | 24% vs 50% | 10% vs 38% |
Gao et al[15] | IB | IA-IIIB | Sintilimab | 2 | 40 | Safety | 20% | 40% | 16% |
NEOMUN[16] | II | II-IIIA | Pembrolizumab | 2 | 15 | Safety and feasibility | 28% | 27% | 13% |
IONESCO[17] | II | IB-IIIA | Durvalumab | 3 | 46 | % R0 | 8% | 18% | 7% |
Shu et al[19] | II | IB-IIIA | Atezolizumab + carboplatin + nab-paclitaxel | 4 | 30 | MPR | 63% | 57% | 33% |
NADIM[20] | II | IIIA | Nivolumab + carboplatin + paclitaxel | 3 | 46 | PFS 24 mo | 76% | 83% | 63% |
SAK 16/14[21] | II | IIIA | Cisplatin + docetaxel followed by durvalumab2 | 2 | 62 | DFS 12 mo | 58% | 60% | 18% |
- Citation: Aguado C, Chara L, Antoñanzas M, Matilla Gonzalez JM, Jiménez U, Hernanz R, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy. World J Clin Oncol 2022; 13(5): 314-322
- URL: https://www.wjgnet.com/2218-4333/full/v13/i5/314.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i5.314